Immix Biopharma (IMMX) Income from Continuing Operations (2021 - 2026)
Immix Biopharma (IMMX) reported Income from Continuing Operations of 10086687.0 for Q1 2026, down 122.05% on a YoY basis from 45744448.93 in Q1 2025, and down 317.98% sequentially from 2413182.0 in Q4 2025.
Immix Biopharma (IMMX) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 6 years of Income from Continuing Operations data on file, last reported at 10086687.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 122.05% year-over-year to 10086687.0; the trailing twelve-month figure through Mar 2026 stood at 26708124.0 (down 3259.47% YoY), and the FY2025 full-year result was 21163965.0, down 1236.49% from the prior year.
- Income from Continuing Operations slipped to 10086687.0 in Q1 2026, from 2413182.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 15302762.0 in Q4 2024 to a low of 10086687.0 in Q1 2026.
- A 5-year average of 2975154.88 and a median of 3598212.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 649.04% in 2022 and surged 1965.89% in 2024, its largest moves.
- Tracing IMMX's Income from Continuing Operations over 5 years: stood at 2053268.0 in 2022, then surged by 60.06% to 820134.0 in 2023, then surged by 1965.89% to 15302762.0 in 2024, then tumbled by 115.77% to 2413182.0 in 2025, then slumped by 317.98% to 10086687.0 in 2026.
- Business Quant data shows IMMX's Income from Continuing Operations at 10086687.0 in Q1 2026, 2413182.0 in Q4 2025, and 7585692.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Immix Biopharma | 473.68 Mn | 473.68 Mn | - | -10.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.09 Mn |
| Dec 31, 2025 | -2.41 Mn |
| Sep 30, 2025 | -7.59 Mn |
| Jun 30, 2025 | -6.62 Mn |
| Mar 31, 2025 | -4.54 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Sep 30, 2024 | -7.15 Mn |
| Jun 30, 2024 | -4.41 Mn |
| Mar 31, 2024 | -5.33 Mn |
| Dec 31, 2023 | -820,134.00 |
| Sep 30, 2023 | -4.34 Mn |
| Jun 30, 2023 | -3.60 Mn |
| Mar 31, 2023 | -2.50 Mn |
| Dec 31, 2022 | -2.05 Mn |
| Sep 30, 2022 | -1.54 Mn |
| Jun 30, 2022 | -1.56 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -22.76 Mn |
| Sep 30, 2021 | -403,265.00 |
| Jun 30, 2021 | -208,638.00 |